At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed primary peritoneal carcinoma, fallopian tube, or ovarian carcinoma Stage III with >1 cm residual disease after surgery or Stage IV
- ✓Appropriate surgical staging with tissue available for histologic evaluation, or unresectable at diagnosis
- ✓Eligible histologic types: serous, endometrioid, mucinous, undifferentiated, clear cell, mixed epithelial, transitional cell, malignant Brenner's tumor, or adenocarcinoma NOS
- ✓Must initiate chemotherapy within 12 weeks of surgery
- ✕Prior chemotherapy within 5 years
- ✕Known brain metastases
- ✕Concurrent investigational agents
- ✕Uncontrolled intercurrent illness including active infection, symptomatic heart failure, unstable angina, arrhythmia, or psychiatric illness limiting compliance
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
In Brief
A Phase 2 clinical trial evaluating paclitaxel, carboplatin, and 1 other intervention for Brenner Tumor and 8 related conditions. Completed, enrolled 56 participants across 1 site.
Detailed Summary
This phase II trial is studying the side effects of giving erlotinib together with carboplatin and paclitaxel and to see how well it works in treating patients with stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy such as carboplatin and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die.
Study Details
Timeline
Interventions
Given IV
Given IV
Given PO